Real-World Utilization, Treatment Patterns, Tolerability, and Effectiveness of Zanidatamab in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma in the United States

Jazz Pharmaceuticals

Summary

The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: 1. Histologically confirmed HER2-positive (defined as IHC3+ or IHC2+ with ISH positivity) locally advanced or metastatic GEA (HER2+ la/m GEA) 2. Documented plan to initiate a zanidatamab-containing therapy as first line (1L) treatment 3. Sufficient cognitive capacity and language proficiency to complete patient-reported outcomes (PRO) questions 4. 18 years of age or older on the date of initiating 1L zanidatamab-containing therapy Exclusion criteria: 1. Receiving a zanidatamab-containing therapy as part of a clinical trial or expanded access program 2. Received zanidatam…

Interventions

Drug
Zanidatamab
Administered via intravenous (IV) infusion

Locations (2)

UCI Health - Chao Family Comprehensive Cancer Center
Orange, California
University of Texas - MD Anderson Cancer Center Gastrointestinal Cancer Center
Houston, Texas

Real-World Utilization, Treatment Patterns, Tolerability, and Effectiveness of Zanidatamab in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma in the United States

Summary

Eligibility

Interventions

Locations (2)

Run this study?

Details

Conditions